open access

Vol 26, No 4 (2022)
Original paper
Published online: 2022-12-29
Get Citation

Sensitivity and specificity of serum cystatin C and creatinine in detecting early stages of chronic kidney disease in Vietnamese patients with hypertension

Ha Nguyen1, Le Nguyen2, Tri Nguyen3, Phuc Le4, Thang Nguyen4, Nhut Nguyen5, Kien Nguyen1
DOI: 10.5603/AH.a2022.0021
·
Arterial Hypertension 2022;26(4):153-163.
Affiliations
  1. Department of Physiology, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam
  2. Department of Physiology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
  3. Department of Gerontology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
  4. Department of Pharmacology and Clinical Pharmacy, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam
  5. Faculty of Pharmacy, Nam Can Tho University, Can Tho City, Vietnam

open access

Vol 26, No 4 (2022)
ORIGINAL PAPERS
Published online: 2022-12-29

Abstract

Background: Hypertension is one of the most common diseases worldwide, especially in Viet Nam. Screening for early-stage chronic kidney disease (CKD) in patients with hypertension remains controversial. We aimed to analyze the sensitivity and specificity of serum cystatin C and serum creatinine in detecting early-stage kidney function loss as a complication in hypertensive patients.

Material and methods: From January 2013 to October 2018, 304 patients first-time diagnosed with primary hypertension at University Medical Center Ho Chi Minh City participated in this cross-sectional study. Collected data includes anthropometric indicators, measured glomerular filtration rate (GFR) by plasma 99mTc-diethylenetriaminepentaacetic clearance, serum cystatin C (ScysC), and serum creatinine (Scr).

Results: ScysC level was significantly reciprocal correlation between renal radiography (r = 0.781, p < 0.001). The cutoff value for the identification of GFR < 80 mL/min/1.73 m2 was ScysC > 1.06 mg/L with a sensitivity of 90.8% and specificity of 90.6%, AUC was 0.90. The sensitivity and specificity of ScysC for the identification of GFR < 70 mL/min/1.73 m2 and GFR < 60 mL/min/1.73 m2 was 96.6%, 100% and 98.8%, 99.3%, respectively. Among 14 estimated glomerular filtration formulas used in this study, eGFR-cysC-Filler-Lepage had the highest sensitivity and specificity for identifying GFR < 80 mL/min/1.73 m2 (79.8% and 100%, respectively). eGFR-cysC-LeBrion had the highest sensitivity and specificity for the identification of GFR < 70 mL/min/1.73 m2 and GFR < 60 mL/min/1.73 m2 (97.6%, 96.9% and 100%, 97%; respectively).

Conclusion: The sensitivity and specificity of ScysC were significantly higher than Scr. The eGFR-cysC-Filler-Lepage formula had the highest sensitivity and specificity in detecting the early stages of CKD.

Abstract

Background: Hypertension is one of the most common diseases worldwide, especially in Viet Nam. Screening for early-stage chronic kidney disease (CKD) in patients with hypertension remains controversial. We aimed to analyze the sensitivity and specificity of serum cystatin C and serum creatinine in detecting early-stage kidney function loss as a complication in hypertensive patients.

Material and methods: From January 2013 to October 2018, 304 patients first-time diagnosed with primary hypertension at University Medical Center Ho Chi Minh City participated in this cross-sectional study. Collected data includes anthropometric indicators, measured glomerular filtration rate (GFR) by plasma 99mTc-diethylenetriaminepentaacetic clearance, serum cystatin C (ScysC), and serum creatinine (Scr).

Results: ScysC level was significantly reciprocal correlation between renal radiography (r = 0.781, p < 0.001). The cutoff value for the identification of GFR < 80 mL/min/1.73 m2 was ScysC > 1.06 mg/L with a sensitivity of 90.8% and specificity of 90.6%, AUC was 0.90. The sensitivity and specificity of ScysC for the identification of GFR < 70 mL/min/1.73 m2 and GFR < 60 mL/min/1.73 m2 was 96.6%, 100% and 98.8%, 99.3%, respectively. Among 14 estimated glomerular filtration formulas used in this study, eGFR-cysC-Filler-Lepage had the highest sensitivity and specificity for identifying GFR < 80 mL/min/1.73 m2 (79.8% and 100%, respectively). eGFR-cysC-LeBrion had the highest sensitivity and specificity for the identification of GFR < 70 mL/min/1.73 m2 and GFR < 60 mL/min/1.73 m2 (97.6%, 96.9% and 100%, 97%; respectively).

Conclusion: The sensitivity and specificity of ScysC were significantly higher than Scr. The eGFR-cysC-Filler-Lepage formula had the highest sensitivity and specificity in detecting the early stages of CKD.

Get Citation

Keywords

cystatin C; creatinine; chronic kidney disease; Vietnamese

About this article
Title

Sensitivity and specificity of serum cystatin C and creatinine in detecting early stages of chronic kidney disease in Vietnamese patients with hypertension

Journal

Arterial Hypertension

Issue

Vol 26, No 4 (2022)

Article type

Original paper

Pages

153-163

Published online

2022-12-29

Page views

480

Article views/downloads

68

DOI

10.5603/AH.a2022.0021

Bibliographic record

Arterial Hypertension 2022;26(4):153-163.

Keywords

cystatin C
creatinine
chronic kidney disease
Vietnamese

Authors

Ha Nguyen
Le Nguyen
Tri Nguyen
Phuc Le
Thang Nguyen
Nhut Nguyen
Kien Nguyen

References (30)
  1. Zhou B, Perel P, Mensah GA, et al. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021; 18(11): 785–802.
  2. Kingue S, Ngoe CN, Menanga AP, et al. Prevalence and Risk Factors of Hypertension in Urban Areas of Cameroon: A Nationwide Population-Based Cross-Sectional Study. J Clin Hypertens (Greenwich). 2015; 17(10): 819–824.
  3. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2020; 75(1 Suppl 1): A6–A7.
  4. Kobori H, Nangaku M, Navar LG, et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007; 59(3): 251–287.
  5. Barri YM. Hypertension and kidney disease: a deadly connection. Curr Hypertens Rep. 2008; 10(1): 39–45.
  6. Services USDoHaH. The Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. ; 2014.
  7. Watanabe S, Okura T, Liu J, et al. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res. 2003; 26(11): 895–899.
  8. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010; 55(4): 622–627.
  9. Levey AS, Inker LA. GFR as the "Gold Standard": Estimated, Measured, and True. Am J Kidney Dis. 2016; 67(1): 9–12.
  10. Ristiniemi N. Quantification and Clinical relevance of Cystatin C. Painosalama, Oy – Turku, Finland 2014: Finland.
  11. Pasala S, Carmody JB. How to use… serum creatinine, cystatin C and GFR. Arch Dis Child Educ Pract Ed. 2017; 102(1): 37–43.
  12. Costanzo MR, Barasch J. Creatinine and Cystatin C: Not the Troponin of the Kidney. Circulation. 2018; 137(19): 2029–2031.
  13. Fan Li, Levey AS, Gudnason V, et al. Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test. Nephrol Dial Transplant. 2014; 29(6): 1195–1203.
  14. Baxmann AC, Ahmed MS, Marques NC, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol. 2008; 3(2): 348–354.
  15. Finney H, Newman DJ, Price CP. Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. Ann Clin Biochem. 2000; 37 ( Pt 1): 49–59.
  16. Redon J, Morales-Olivas F, Galgo A, et al. MAGAL Group. Urinary albumin excretion and glomerular filtration rate across the spectrum of glucose abnormalities in essential hypertension. J Am Soc Nephrol. 2006; 17(12 Suppl 3): S236–S245.
  17. Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens. 2015; 24(3): 295–300.
  18. van der Laan SW, Fall T, Soumaré A, et al. Cystatin C and Cardiovascular Disease: A Mendelian Randomization Study. J Am Coll Cardiol. 2016; 68(9): 934–945.
  19. Grubb A. Cystatin C as a biomarker in kidney disease. In: Edelstein E. ed. Biomarkers of Kidney Disease. Elsevier 2011: 291–312.
  20. Grubb A, Nyman U, Björk J. Improved estimation of glomerular filtration rate (GFR) by comparison of eGFRcystatin C and eGFRcreatinine. Scand J Clin Lab Invest. 2012; 72(1): 73–77.
  21. Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest. 1985; 45(2): 97–101.
  22. Ozer B, Baykal A, Dursun B, et al. Can Cystatin C Be a Better Marker for the Early Detection of Renal Damage in Primary Hypertensive Patients? Ren Fail. 2005; 27(3): 247–253.
  23. Salgado JV, França AK, Cabral NA, et al. Cystatin C, kidney function, and cardiovascular risk factors in primary hypertension. Rev Assoc Med Bras (1992). 2013; 59(1): 21–27.
  24. Janowski R, Kozak M, Jankowska E, et al. Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nat Struct Biol. 2001; 8(4): 316–320.
  25. Toan PQ. Concentration of serum cystatin C and urine cystatin C on type-2 diabetic patients with kidney injury. Military Hospital. 2015; 103.
  26. Mussap M, Montini G, Amici G, et al. Cystatin C compared to Inulin clearance for the estimation of GFR in preterm newborns. Clin Chem Lab Med. 1999; 13: 506–509.
  27. Orlando R, Mussap M, Plebani M, et al. Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem. 2002; 48(6 Pt 1): 850–858.
  28. Macisaac RJ, Tsalamandris C, Thomas MC, et al. Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia. 2006; 49(7): 1686–1689.
  29. Omaygenç MO, Özcan ÖU, Çakal B, et al. Cystatin C and uncontrolled hypertension. Anatol J Cardiol. 2020; 24(5): 309–315.
  30. Tomson CRV, Cheung AK, Mann JFE, et al. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158(11): 825–830.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl